Morgan Stanley Maintains Underweight on Biogen, Raises Price Target to $302

Morgan Stanley maintains Biogen (NASDAQ:BIIB) with a Underweight and raises the price target from $261 to $302.

Benzinga · 02/06/2020 15:02

Morgan Stanley maintains Biogen (NASDAQ:BIIB) with a Underweight and raises the price target from $261 to $302.